Drug industry anxious about scrapping price regulation schemeBMJ 2008; 336 doi: https://doi.org/10.1136/bmj.39526.738345.DB (Published 27 March 2008) Cite this as: BMJ 2008;336:686
- Andrew Cole
Almost half (46%) of the United Kingdom’s drug companies expect to cut back on clinical trials in the coming year because of continued uncertainty about future arrangements for pricing drugs.
In a survey of more than 100 companies earlier this month on behalf of the Association of the British Pharmaceutical Industry and the Confederation of British Industry three quarters said they had little confidence in the current UK market environment, and 83% expected things to get worse in the next year.
The survey also showed that 30% of drug companies expect to cut staff in the next year, and more than …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial